About 10 percent of American adults are now taking GLP-1 medications for weight loss, and the food industry is paying attention. These drugs don't just suppress appetite—they rewire how the brain processes hunger signals and how the stomach functions. Users often develop heightened sensitivity to flavors, aversions to greasy foods, and a tendency to eat slowly. For food companies, this represents a fundamental shift in how they should design products.
The change is less about creating craveable snacks and more about building foods that feel tolerable and comfortable to eat. David Lundahl, founder of InsightsNow, notes that texture has become critical. "Texture can be a dealbreaker," he says. When someone is eating smaller portions, every bite matters more.
Nutrition in smaller bites
Here's the real challenge: if you're eating a fraction of what you used to, you need to pack more nutrition into each meal. Protein, fiber, and essential micronutrients become non-negotiable. Food manufacturers are responding by rethinking portion sizes, fortifying products with vitamins and minerals, and developing new protein formats that work in smaller servings.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxDanone's OIKOS Fusion became the first cultured dairy drink designed specifically for GLP-1 users. In their research, the company found something telling: GLP-1 users wanted small, portable products they could grab on the go. "Our current ecosystem is not built for smaller portion sizes," says Whitney Evans, Director of Nutrition and Scientific Affairs at Danone U.S. "And particularly for this population, it's really difficult to eat on the move."
But here's what's being overlooked: 90 percent of GLP-1 users had no contact with a registered dietitian before starting the medication. Most people beginning these drugs receive no guidance on what nutrition actually matters. This gap matters because eating well on GLP-1s requires intentionality. You can't rely on appetite to tell you when to eat.
Danone has started filling this gap with tools like a website offering nutrition recommendations from registered dietitians and guidelines pharmacists can share with patients as they pick up prescriptions. The goal isn't just to sell more products—it's to help people actually eat well while taking these medications.
Whitney Evans makes a broader point worth sitting with: "Similar nutritional needs apply to both GLP-1 users and non-users. If we all focus on eating a more nutrient-dense diet and prioritize essential nutrients, we're going to be better off to the point where maybe we won't need medication to be doing some of this work for us."
The food industry's response to GLP-1 adoption shows how shifts in consumer health can drive real innovation. The question now is whether this focus on smaller portions and nutrient density sticks around—whether it becomes how we all think about eating, not just how GLP-1 users have to eat.
